Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Susceptibility testing–based fourth-line Helicobacter pylori eradication therapy
jRCTs031180208Completed
- Sponsor
- Yokohama City University
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vonoprazan, amoxicillin, clarithromycin and metronidazole in Helicobacter pylori infection, sponsored by Yokohama City University. Primary endpoint: Eradication rate. Started Jul 2017; status: completed.
02
Drugs
vonoprazanamoxicillinclarithromycinmetronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on jRCTs031180208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180208.